Holen Sie sich die Stockscreener-App
6.92
8.81%
0.56
Handel nachbörslich:
6.93
0.010
+0.14%
Schlusskurs vom Vortag:
$6.36
Offen:
$6.41
24-Stunden-Volumen:
1.67M
Relative Volume:
1.73
Marktkapitalisierung:
$427.37M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-130.41M
KGV:
-3.0893
EPS:
-2.24
Netto-Cashflow:
$-67.76M
1W Leistung:
+41.51%
1M Leistung:
+51.75%
6M Leistung:
+3.75%
1J Leistung:
+16.30%
1-Tages-Spanne:
$6.41
$7.05
1-Wochen-Bereich:
$4.795
$7.44
52-Wochen-Spanne:
$3.5001
$12.40
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Firmenname
Monte Rosa Therapeutics Inc
Sektor
Branche
Telefon
617-949-2643
Adresse
321 HARRISON AVENUE, BOSTON
Vergleichen Sie GLUE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
6.92 | 392.79M | 0 | -130.41M | -67.76M | -2.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
386.95 | 99.26B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
598.71 | 62.06B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.17 | 59.21B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
731.77 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
342.89 | 36.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | Eingeleitet | Wedbush | Outperform |
| 2023-01-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | Eingeleitet | UBS | Buy |
| 2022-08-15 | Eingeleitet | Jefferies | Buy |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-10-14 | Eingeleitet | SVB Leerink | Mkt Perform |
Alle ansehen
Monte Rosa Therapeutics Inc Aktie (GLUE) Neueste Nachrichten
Analysis Recap: Is Monte Rosa Therapeutics Inc stock a hidden gemMarket Risk Report & Intraday High Probability Alerts - خودرو بانک
Monte Rosa: H1 2026 NEK7 Protein Degrader MRT-8102 Data Could Be Added POC - Seeking Alpha
Wedbush Analysts Reduce Earnings Estimates for GLUE - MarketBeat
CEO Moves: Will Monte Rosa Therapeutics Inc. benefit from geopolitical trendsTreasury Yields & Proven Capital Preservation Methods - خودرو بانک
Monte Rosa Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:GLUE - Benzinga
Breakouts Watch: Is Monte Rosa Therapeutics Inc. stock showing strong momentumEarnings Overview Summary & Weekly Stock Performance Updates - خودرو بانک
AI Stocks: What is Monte Rosa Therapeutics Inc. s revenue forecastJuly 2025 Breakouts & Verified Swing Trading Watchlists - خودرو بانک
Institution Moves: Does Monte Rosa Therapeutics Inc stock have upside surprise potentialInsider Selling & Weekly Watchlist of Top Performers - خودرو بانک
Monte Rosa Therapeutics And The Promise Of Molecular Glue Degraders - Seeking Alpha
Monte Rosa's Stock Gains on Signing $5.7B Licensing Deal With Novartis - Yahoo Finance
Monte Rosa, Novartis stick together in new $5.7B deal - BioWorld MedTech
Monte Rosa Therapeutics (GLUE) Soars 44.1%: Is Further Upside Left in the Stock? - Yahoo Finance
Novartis builds on Monte Rosa collaboration with $5.7 billion deal - MarketScreener
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock? - simplywall.st
Monte Rosa Therapeutics Stock Scores Biggest Gain In Nearly A Year On $5.7B Novartis Deal For Immune-Mediated Diseases - Stocktwits
Novartis Sticks With Monte Rosa In Search For New Molecular Glue Degraders - insights.citeline.com
Monte Rosa Therapeutics and Novartis agree on second billion-dollar deal - European Biotechnology Magazine
Support Test: Can Monte Rosa Therapeutics Inc ride the EV waveJuly 2025 Analyst Calls & Expert-Curated Trade Recommendations - خودرو بانک
Swing Trade: Is TFSL a defensive stockQuarterly Growth Report & Low Risk Profit Maximizing Plans - خودرو بانک
Novartis, Monte Rosa Therapeutics join hands for Degraders to treat Immune-mediated diseases - Medical Dialogues
Stock Report: Does Monte Rosa Therapeutics Inc have pricing power2025 Dividend Review & Free AI Powered Buy and Sell Recommendations - خودرو بانک
Aug Chart Watch: Will SNBR stock benefit from M AJuly 2025 PreEarnings & AI Driven Stock Reports - خودرو بانک
Monte Rosa Therapeutics stock rises as TD Cowen reiterates Buy on expanded Novartis deal - Investing.com Canada
Monte Rosa & Novartis Partner to Develop Immune-Mediated Disease Treatments - Contract Pharma
Risk Hedge: Is Monte Rosa Therapeutics Inc stock a hidden gemJuly 2025 PreEarnings & AI Enhanced Execution Alerts - خودرو بانک
Novartis, Monte Rosa Ink Up To $5.7B 'Molecular Glue' Deal - Law360
Monte Rosa soars pre-market! Secures $5.7 billion licensing agreement with Novartis AG - 富途牛牛
Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments - Benzinga
Monte Rosa inks $5.7B deal with Novartis for immune disease drug development - The Business Journals
Monte Rosa stock rises after pact with Novartis (GLUE:NASDAQ) - Seeking Alpha
Wedbush Raises Price Target on Monte Rosa Therapeutics to $19 From $17, Maintains Outperform Rating - MarketScreener
Big Money Moves: What dividend growth rate does Monte Rosa Therapeutics Inc offer2025 Volume Leaders & Verified Chart Pattern Trade Signals - خودرو بانک
Monte Rosa Therapeutics: Bridging Potential and Performance - StocksToTrade
Novartis dives deeper into protein degraders with second Monte Rosa deal - BioPharma Dive
Novartis signs up to $5.7 billion licensing deal with Monte Rosa Therapeutics - Reuters
Up to $5.7 billion on the line in new Novartis and Monte Rosa deal - The Pharma Letter
Monte Rosa Therapeutics Inc. stock trend forecastDip Buying & Verified Momentum Stock Watchlist - newser.com
Sentiment Watch: What are the risks of holding Monte Rosa Therapeutics IncTreasury Yields & Expert-Curated Trade Recommendations - خودرو بانک
Novartis signs up to US$5.7 billion licensing deal with Monte Rosa Therapeutics - BNN Bloomberg
Updated: Novartis extends deal spree with $120M for Monte Rosa’s immune degraders - Endpoints News
Monte Rosa stock soars after $120M Novartis collaboration deal By Investing.com - Investing.com Nigeria
Monte Rosa stock soars after $120M Novartis collaboration deal - Investing.com
Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases - GlobeNewswire
$5.7 Billion Biotech Deal: Monte Rosa Teams with Novartis on Revolutionary Protein Degrader Platform - Stock Titan
Is a relief rally coming for Monte Rosa Therapeutics Inc. holdersWeekly Market Outlook & Precise Swing Trade Alerts - newser.com
Risk adjusted return profile for Monte Rosa Therapeutics Inc. analyzedPortfolio Value Summary & Accurate Intraday Trade Tips - newser.com
Can technical indicators confirm Monte Rosa Therapeutics Inc.’s reversalJuly 2025 Momentum & AI Enhanced Execution Alerts - newser.com
Can momentum traders help lift Monte Rosa Therapeutics Inc.Weekly Trend Report & Capital Efficiency Focused Strategies - newser.com
Visual analytics tools that track Monte Rosa Therapeutics Inc. performance2025 Geopolitical Influence & Free Technical Pattern Based Buy Signals - newser.com
Will Monte Rosa Therapeutics Inc. stock go up soonJuly 2025 Price Swings & Verified Trade Idea Suggestions - newser.com
Is Monte Rosa Therapeutics Inc. building a consolidation baseJuly 2025 Decliners & Daily Entry Point Alerts - newser.com
Finanzdaten der Monte Rosa Therapeutics Inc-Aktie (GLUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Monte Rosa Therapeutics Inc-Aktie (GLUE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Leo Chandra P. | Director |
Mar 24 '25 |
Buy |
5.84 |
10,000 |
58,383 |
10,000 |
| Versant Venture Capital VI, L. | 10% Owner |
Oct 28 '24 |
Sale |
9.66 |
89,990 |
869,240 |
2,007,948 |
| Versant Venture Capital VI, L. | 10% Owner |
Oct 29 '24 |
Sale |
9.16 |
67,905 |
621,801 |
1,573,453 |
0.07%
1.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):